CRAF Mutations in Lung Cancer Can Be Oncogenic and Predict Sensitivity to Combined Type II RAF and MEK Inhibition

Oncogene - United Kingdom
doi 10.1038/s41388-019-0866-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

MEK1 Mutations Confer Resistance to MEK and B-Raf Inhibition

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2012English

Molecular Signaling in Multiple Myeloma: Association of RAS/RAF Mutations and MEK/ERK Pathway Activation

Oncogenesis
Cancer ResearchMolecular Biology
2017English

Combined MEK and BCL-XL Inhibition Kills KRAS -Mutant Cells

Cancer Discovery
Oncology
2012English

Reduced Phosphorylation of Ribosomal Protein S6 Is Associated With Sensitivity to MEK Inhibition in Gastric Cancer Cells

Cancer Science
Cancer ResearchMedicineOncology
2016English

Can Exhaled NO Fraction Predict Radiotherapy-Induced Lung Toxicity in Lung Cancer Patients?

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2012English

Loss-Of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer

PLoS ONE
Multidisciplinary
2015English

Targeting Alterations in the RAF–MEK Pathway

Cancer Discovery
Oncology
2019English

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

Cancer Cell
Cancer ResearchOncologyCell Biology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy